Interferon beta-1a is under clinical development by Synairgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Interferon beta-1a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Interferon beta-1a overview
Interferon beta-1a (AZD9412, SNG001) was under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other strains including alpha, beta and gamma COVID strains. The drug candidate is administered through inhalation. It targets interferon alpha receptor 1 and 2. It was also under development for exacerbation and viral pneumonia caused by pandemic H1N1 (swine flu), H5N1 infection, asthma exacerbations and middle east respiratory syndrome (MERS).
It is under development for COPD.
Synairgen is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma, COVID-19 and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) in Phase II clinical trials for chronic obstructive pulmonary disease (COPD) and COVID-19. The company in partnership with Pharmaxis investigating, lysyl oxidase-like protein 2 (LOXL2), a small molecule inhibitor in Phase I clinical trials for the treatment of fibrotic disease. The company develops drugs and tissue models based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells, and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.
For a complete picture of Interferon beta-1a’s drug-specific PTSR and LoA scores, buy the report here.